Current and historical daily PE Ratio for HALO (
Halozyme Therapeutics Inc
) from 2004 to May 20 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Halozyme Therapeutics stock (HALO) PE ratio as of May 20 2024 is 18.58.
More Details
Halozyme Therapeutics Inc (HALO) PE Ratio (TTM) Chart
Halozyme Therapeutics Inc (HALO) PE Ratio (TTM) Historical Data
View and export this data going back to 2004. Start your Free Trial
Total 1233
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Halozyme Therapeutics PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-05-21 | 18.6 | 2024-03-18 | 19.1 |
| 2024-05-20 | 18.6 | 2024-03-15 | 19.4 |
| 2024-05-17 | 18.5 | 2024-03-14 | 19.3 |
| 2024-05-16 | 18.8 | 2024-03-13 | 19.6 |
| 2024-05-15 | 18.9 | 2024-03-12 | 19.9 |
| 2024-05-14 | 18.1 | 2024-03-11 | 19.5 |
| 2024-05-13 | 18.0 | 2024-03-08 | 19.8 |
| 2024-05-10 | 17.8 | 2024-03-07 | 19.8 |
| 2024-05-09 | 18.1 | 2024-03-06 | 19.8 |
| 2024-05-08 | 17.4 | 2024-03-05 | 19.6 |
| 2024-05-07 | 17.0 | 2024-03-04 | 19.4 |
| 2024-05-06 | 16.9 | 2024-03-01 | 19.5 |
| 2024-05-03 | 16.5 | 2024-02-29 | 18.9 |
| 2024-05-02 | 16.4 | 2024-02-28 | 18.8 |
| 2024-05-01 | 16.2 | 2024-02-27 | 18.9 |
| 2024-04-30 | 15.7 | 2024-02-26 | 18.8 |
| 2024-04-29 | 16.0 | 2024-02-23 | 19.2 |
| 2024-04-26 | 15.9 | 2024-02-22 | 18.8 |
| 2024-04-25 | 15.9 | 2024-02-21 | 18.2 |
| 2024-04-24 | 16.2 | 2024-02-20 | 17.1 |
| 2024-04-23 | 16.1 | 2024-02-16 | 17.1 |
| 2024-04-22 | 16.0 | 2024-02-15 | 17.0 |
| 2024-04-19 | 16.0 | 2024-02-14 | 16.6 |
| 2024-04-18 | 15.6 | 2024-02-13 | 16.4 |
| 2024-04-17 | 15.7 | 2024-02-12 | 16.9 |
| 2024-04-16 | 15.9 | 2024-02-09 | 16.8 |
| 2024-04-15 | 16.0 | 2024-02-08 | 16.7 |
| 2024-04-12 | 15.9 | 2024-02-07 | 16.7 |
| 2024-04-11 | 16.3 | 2024-02-06 | 16.6 |
| 2024-04-10 | 16.2 | 2024-02-05 | 16.0 |
| 2024-04-09 | 16.6 | 2024-02-02 | 16.0 |
| 2024-04-08 | 16.5 | 2024-02-01 | 16.2 |
| 2024-04-05 | 17.0 | 2024-01-31 | 16.0 |
| 2024-04-04 | 16.4 | 2024-01-30 | 16.0 |
| 2024-04-03 | 16.6 | 2024-01-29 | 16.3 |
| 2024-04-02 | 16.7 | 2024-01-26 | 16.2 |
| 2024-04-01 | 17.1 | 2024-01-25 | 16.4 |
| 2024-03-28 | 16.8 | 2024-01-24 | 16.6 |
| 2024-03-27 | 19.3 | 2024-01-23 | 16.5 |
| 2024-03-26 | 19.0 | 2024-01-22 | 16.1 |
| 2024-03-25 | 19.2 | 2024-01-19 | 16.2 |
| 2024-03-22 | 19.0 | 2024-01-18 | 16.6 |
| 2024-03-21 | 19.1 | 2024-01-17 | 17.1 |
| 2024-03-20 | 19.1 | 2024-01-16 | 17.2 |
| 2024-03-19 | 19.3 | 2024-01-12 | 16.3 |
Halozyme Therapeutics Inc (HALO) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Halozyme Therapeutics Inc
NAICS : 325414
SIC : 2836
ISIN : US40637H1095
Share Class Description:
HALO: Ordinary SharesCompare
Compare
Traded in other countries / regions
HALO.USA0J2O.UKRV7.GermanyHALO.Mexico IPO Date
2004-03-12Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers